ADCs and TKIs Plus Immunotherapy Signal the Future of Urothelial Carcinoma and RCC - OncLive

Benjamin Garmezy, MD, discussed the positive trajectory of antibody-drug conjugates and immunotherapy in urothelial carcinoma, highlighting the importance of considering individual patient eligibility for treatments like first-line chemotherapy.

Antibody-drug conjugates (ADCs) and TKIs combined with immunotherapy and other emerging agents are improving response rates in patients with urothelial cancer and renal cell carcinoma (RCC) respectiv… [+14463 chars]

full article...